- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02370056
Evaluation of 3D Visualization for Total Colectomy (3Dvs2DforUC)
Comparative Assessment of Three-dimensional vs. Conventional Laparoscopy in a Total Colectomy Model for Ulcerative Colitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Three-dimensional (3D) visualization technology for laparoscopy has been proposed, since the early 1990's, as a method to facilitate laparoscopic performance. However, early 3D laparoscopic technology was limited in terms of image quality, so that its use had not been implemented. The latest technical developments ensure high-definition 3D visualization with the same quality that current two-dimensional (2D) systems provide.
The anticipated advantages of 3D laparoscopic visualization for the surgeon are greater accuracy and speed in manual skills, translating to decreased operative time, reduced learning curve, and superior safety . It was reported that, 3D laparoscopic visualization offers significant advantages in enhancing laparoscopic performance, even in novice surgeons, comparing to the 2D systems . We hypothesize that 3D visualization may allow surgeons to reduce the overall operating time with a rate of 10% with comparable perioperative and postoperative outcomes. The primary endpoint of this study is to determine the feasibility of the laparoscopic approach using 3D visualization in the surgical treatment of ulcerative colitis. Secondary endpoints are to determine whether 3D visualization confers benefits such as reduced operating time and intra-operative complications with comparable postoperative outcomes.
Device Description: The EXERA III Universal Platform will be used in this study, in conjunction with the ENDOEYE FLEX 3D. The ENDOEYE FLEX 3D can also be used in 2D mode, by utilizing a programmed button on the handle of the scope, or by using the 2D/3D button on the 3D Visualization Unit. The articulating tip of the ENDOEYE FLEX allows for the scope to be used in both single-site and multi-port procedures, providing critical views and allowing a bird's eye view so that the scope is out of the way of other instruments (while still capturing the image at the surgical site). All equipment used in this trial has been cleared under 510(k) approval by the FDA, and has been on the market in the US since April 2013.
The Olympus HD 3D Laparoscopic Surgical Video System consists of the following components:
- CV-190 Processor
- CLV-190 Light Source
- 3DV-190 3D Visualization Unit
- LMD-2451MT/3G4 Sony 24" 3D Monitor
- IMH-20 Image Capture System
- UHI-4 Insufflator
- K10021611 Cart
- OL-0015-08 Tall Rollstand
- LTF-190-10-3D ENDOEYE FLEX 3D Videoscope
- 3D glasses (regular and clip-on styles)
Study Size:Mean operating time for laparoscopic subtotal colectomy for medically refractory UC was reported longer with a comparison to open surgery in the recently published studies.
Therefore the effort to decrease operating time in laparoscopic colectomy has gained importance. We assumed that, in order to be able to determine a 10% reduction in mean operating time, each group should include 27 patients (80% power and 5% significance).
Patients who will undergo laparoscopic total abdominal colectomy (TAC) for UC will be included in the study. All subjects will be randomized into two groups: 3D laparoscopy, and 2D laparoscopy. Three staff surgeons (EG, HK, FR) at the department of colorectal surgery, Cleveland Clinic, Ohio will perform the procedures with 2D and 3D laparoscopy. Each surgeon will perform 9 total colectomies with 3D, and 9 total colectomies with the 2D laparoscopy system. In total, 54 patients will be included (27 patients for each group).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Indication for surgery must be Ulcerative Colitis
- Patient age between 18 and 80
- Elective procedure
- BMI between 17 and 30
- Total colectomy with end ileostomy, without proctectomy
Exclusion Criteria:
- Any preoperative diagnosis other than UC
- Patient age< 18, or >80
- Emergency surgery
- Previous gastrointestinal surgery
- BMI>30
- Pregnancy
- Presence of any gastrointestinal tract malignancy
- Segmental colon resections, completion proctectomy, total proctocolectomy, pouch procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 3D Visualization
3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System. This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated. |
Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
|
|
Active Comparator: 2D Visualization
2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System. This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated. |
Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Operating Time
Time Frame: 180 minutes
|
total operating time
|
180 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major Complication
Time Frame: 180 minutes
|
Number of Participants with Intraoperative Complications
|
180 minutes
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCFJJN4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Eli Lilly and CompanyRecruitingUlcerative Colitis, Active Severe | Ulcerative Colitis (UC) | Ulcerative Colitis, Active ModerateUnited States, China, Croatia, France, India, Japan, Israel, Taiwan, Brazil, Serbia, Greece, Hungary, Argentina, Italy, Poland, Czechia, Colombia, Lithuania, Latvia, Ukraine, South Africa, Portugal, Mexico, Canada, Slovakia, Turkey (Türkiye) and more
-
Odyssey TherapeuticsRecruitingUlcerative Colitis (UC) | UC - Ulcerative ColitisAustralia, Austria, Jordan, Poland, Ukraine, New Zealand, Canada, Czechia, Lithuania, Moldova
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; MRSU 938 - Research Center of Saint...Not yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtCompletedUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Alexion Pharmaceuticals, Inc.Immune PharmaceuticalsTerminatedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
-
Palatin Technologies, IncActive, not recruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Merck Sharp & Dohme LLCRecruitingUlcerative Colitis | Colitis UlcerativeUnited States
Clinical Trials on 3-dimensional visualization
-
Felix CorrNot yet recruitingSpinal Diseases | Randomized Controlled Trial | Simulation Training | Endoscopy Simulation | Three-Dimensional | Lumbar Vertebrae
-
Eastern Mediterranean UniversityCompleted
-
University of HawaiiNational Center for Research Resources (NCRR)UnknownPregnancy | Substance Use DisordersUnited States
-
Szeged UniversityCompletedPlacenta DiseasesHungary
-
Sandwell & West Birmingham Hospitals NHS TrustUnknown
-
Cairo UniversityCompleted
-
Juan Crestanello, MDUniversity of Michigan; Edwards LifesciencesWithdrawnCongestive Heart Failure | Mitral Valve Regurgitation | CardiomyopathyUnited States
-
Pusan National University Yangsan HospitalCompletedAmyotrophic Lateral SclerosisKorea, Republic of
-
Case Comprehensive Cancer CenterCompletedBreast CancerUnited States
-
University MariborCompletedHeart Diseases | Cardiovascular Diseases | Coronary Artery Disease | Coronary Heart Disease | Lifestyle | Continuous Glucose Monitoring | Behaviour Change | CGM | Visual AnalyticsSlovenia